Skip to main content


  • 153 Accesses




Is a humanized IgG1κ monoclonal antibody specifically binding to HER2.

Human epidermal growth factor 2 (HER2/Neu), also known as ErbB-2, is a member of the epidermal growth factor receptor (ErbB) family and is notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane receptor tyrosine kinase normally involved in the signal transduction pathways leading to cell growth and differentiation.

HER2 is named because it has similar structure to human epidermal growth factor receptor, or HER1. ErbB2 was named for its similarity to ErbB (avian erythroblastosis oncogene B), the oncogene later found to code for EGFR. Gene cloning showed that neu, HER2, and ErbB2 were the same.

Trastuzumab is approved for treatment of HER2 overexpressing metastatic breast cancer in combination with chemotherapy and as single-agent therapy in those patients with metastasic breast cancer who do not respond to chemotherapy.


This is a preview of subscription content, access via your institution.

Buying options

USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
USD   2,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

(2011). Trastuzumab. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg.

Download citation